PIK3CA and melanoma: While the PI3K pathway is critical to cancer development and regulates activity of multiple immune cell populations in the TME, clinical development of pan-PI3K inhibitors for the treatment of solid tumor malignancies in melanoma, breast, lung, colorectal, and head and neck cancers has faced challenges of inefficacy and clinical toxicity (16–23).